Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBOW: TACE + tislelizumab + lenvatinib vs cisplatin + gemcitabine + tislelizumab in unresectable intrahepatic cholangiocarcinoma
ChiCTR2600124683Phase 3Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in cholangiocarcinoma (CCA) comparing TACE + tislelizumab + lenvatinib with Cisplatin + gemcitabine + tislelizumab (2 arms). Primary endpoint: Overall survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
tislelizumablenvatinibcisplatingemcitabine
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2600124683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124683.